The Shifting Landscape of Lung Cancer Treatment: Why Pathologic Response is Becoming Key
The treatment of resectable non-tiny cell lung cancer (NSCLC) is undergoing a significant evolution. While neoadjuvant immunotherapy plus chemotherapy has demonstrated improvements in event-free survival and pathologic complete response, a crucial question remains: how do we best leverage this progress to optimize patient outcomes?
Beyond Complete Response: The Nuances of Residual Viable Tumor
Traditionally, a pathologic complete response – meaning zero residual viable tumor (RVT) in both the primary tumor and lymph nodes – was considered the gold standard following neoadjuvant therapy. Still, recent research suggests a more nuanced picture. Studies, including the CheckMate 816 trial (NCT02998528), are revealing that even small amounts of RVT can significantly impact event-free survival (EFS).
Specifically, the degree of RVT in the primary tumor (PT) appears to be a strong predictor of EFS. Data shows a hazard ratio of 0.18 for patients with 0% versus >0% RVT-PT. Even incremental increases in RVT – from 0-5% to >5-30%, >30-80% and >80% – correlate with progressively lower 2-year EFS rates (90%, 60%, 57%, and 39% respectively). Each 1% increase in RVT is associated with a 0.017 hazard ratio increase for EFS.
This highlights the importance of precise pathologic response assessment. The current practice of regression grading is being evaluated in multicentre studies like Re-GraDE NSCLC to ensure consistency and accuracy.
Adjuvant Immunotherapy: A More Targeted Approach
The implications of these findings are particularly relevant to the use of adjuvant immunotherapy. A recent editorial published in J Thorac Oncol suggests that adjuvant immunotherapy should not be used in patients achieving a pathologic complete response to neoadjuvant chemoimmunotherapy. This is a significant shift in thinking, moving away from a one-size-fits-all approach towards a more personalized strategy.
Researchers are actively working to develop risk stratification models based on both pathologic response and ypN status (lymph node status) to identify those patients who would truly benefit from adjuvant immunotherapy. This targeted approach aims to maximize the benefits of treatment while minimizing unnecessary exposure to potential side effects.
Pro Tip: Pathologic response, when combined with assessment of both the primary tumor and lymph nodes, provides the most accurate approximation of EFS compared to radiographic response or circulating tumor DNA clearance.
The Future of Lung Cancer Treatment: A Focus on Precision
The emerging consensus is that pathologic response assessment is becoming a crucial survival surrogate in lung cancer. Further research is warranted to fully understand the spectrum of %RVT and its implications across various tumor types. This includes refining our understanding of thresholds beyond pathologic complete response and major pathologic response (≤10% RVT).
The ability to accurately predict EFS based on pathologic response will not only guide treatment decisions but too accelerate the development of new therapies. By identifying biomarkers associated with response and resistance, we can move closer to truly personalized cancer care.
Did you grasp? Neoadjuvant immunotherapy plus chemotherapy improves event-free survival and pathologic complete response, making it a promising treatment option for resectable lung cancer.
FAQ
Q: What is pathologic complete response?
A: Pathologic complete response means there is no evidence of cancer cells remaining in the tissue samples after neoadjuvant therapy.
Q: Why is RVT important?
A: The amount of residual viable tumor (RVT) after neoadjuvant therapy is a strong predictor of event-free survival.
Q: Should all patients receive adjuvant immunotherapy after neoadjuvant chemoimmunotherapy?
A: No, recent evidence suggests adjuvant immunotherapy should not be used in patients with a pathologic complete response.
Q: What is the CheckMate 816 trial?
A: CheckMate 816 (NCT02998528) is a phase 3 trial evaluating neoadjuvant nivolumab plus chemotherapy in patients with resectable lung cancer.
Want to learn more about advancements in lung cancer treatment? Explore our other articles or subscribe to our newsletter for the latest updates.
Related reading